Abstract
Introduction

The application of stem/progenitor cells to injury or disease management will require sufficient cell number, thus necessitating derivation of ex vivo expansion protocols as the native stem cell resource is limited by their availability, typically less than one in every
,000 cells [1, 2] [3] . The use of human-derived serum has been shown to support hBMSC and chondrocyte cell growth; however, these studies are limited by issues of cost and availability [4, 5] . Use of a serum-free growth medium may permit better modelling of differentiation potential [6] [7] [8] , and a serum-free chemically defined medium (CDM) developed by Johansson and Wiles [6] [9] . Following supplementation with fibroblast growth factor-2 (FGF-2), hESCs maintained pluripotency in long-term cultures suggesting FGF-2 as a competence factor in the activin/Nodal pathway [9] . Many tissue regeneration strategies rely on the application of stimulatory agents to induce differentiation following expansion [10, 11] and various factors have been applied to mesenchymal cell populations [12] [13] [14] . Ascorbic acid 2-phosphate (ascorbate), acts as an enzyme co-factor for collagen synthesis and has been shown to enhance the osteogenic response of human osteoblasts in vitro [15] as has dexamethasone, a glucocorticoid hormone which promotes the catabolism of carbohydrates, fats and proteins and antagonizes insulin signalling [12, [16] [17] [18] . The bone morphogenetic proteins (BMPs) are potent mitogens for the formation of new skeletal tissue, and have been extensively studied for their effects on osteogenic and chondrogenic differentiation [19] [20] [21] and the proliferative ability of cells [19, 20, [22] [23] [24] [25] . First described as components of demineralized bone matrix by Urist and coworkers [26] , BMPs are key in the signal transduction of SMAD proteins 1, 5 [27] . [28] although studies with primary bone cells from foetuses at 11-14 weeks after conception (WPC) by Campagloni et al. [29] or [13] [14] [15] [16] Montjovent et al. [30] , indicated the proliferation of foetal bone cells was increased in the presence of dexamethasone and showed that following treatment with vitamin D3, ascorbic acid and ␤-glycerolphosphate, foetal populations displayed enriched ALP activity, with up-regulation of type I collagen, ALP, osteocalcin and RUNX2 gene expression [30] Fig. S1 ). [34] . (Fig. 3A versus Fig. 3B and C) , with minimal expression of type II collagen (Fig. 3D versus Fig. 3E and F) . STRO-1 was seen in selected cells in three conditions (Fig. 3G-I) although not in the cells with the altered nuclear positioning (Fig. 3I) . SOX-9 expression was observed in basal (Fig. 3J) and CDM with activin A/FGF-2 cultures (Fig. 3K) but limited to the cobblestone-like cells in CDM plus BMP-2 (Fig. 3L) . In addition, expression of SOX-2 was observed in the CDM plus BMP-2 cultures only and was restricted to the cobblestone-like cells (Fig. 3M and N versus Fig. 3O) . Expression of OCT4 and TRA-1-60 were not seen in any of the treatments (Fig. S5 ).
. Expansion of cultures in vitro must be tempered with the ability of the cells to maintain a proliferative capacity and stem/progenitor phenotype prior to targeted lineage differentiation. Most tissue culture techniques utilize foetal calf serum (FCS), a complex undefined mixture of factors, although batch variability has been shown to have significant effects on expansion kinetics of human bone marrow stromal cells (hBMSCs)
and 8 which up-regulate runt-related transcription factor 2 (RUNX2, also referred to as CBFA1 or core-binding factor 1) and result in downstream up-regulation of bone matrix proteins type I collagen, osteocalcin and osteopontin, necessary for osteoblast maturation
Various studies have reported on the osteogenic properties of human foetal bone cells. Harris and coworkers demonstrated increased levels of alkaline phosphatase (ALP) and osteocalcin in an immortalized human foetal osteoblastic cell line in the presence of vitamin D3
Biochemical analysis
Quantitative PCR
Real-time qRT-PCR was performed with the Applied Biosystems 7500 Real Time PCR System for primers as illustrated in
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Microarray analysis of CDM plus BMP-2 cultures
To better define the mechanisms behind the altered phenotype in the CDM plus BMP-2 cultures, genome-wide expression array analysis was used to identify differential gene expression compared to basal and CDM with activin A/FGF-2 conditions (Fig. 4) (Fig. 4B) (Fig. 5A) , a pattern repeated for 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (Fig. 5B) (Fig. 5C) , and Wnt inhibitory factor 1 (Fig. 5D) [6, 9] resulted in an undifferentiated phenotype as indicated by reduced amino acid turnover [35] , negligible expression of ALP activity and type I and type II collagens. Expression of STRO-1 and SOX-9, as markers of mesenchymal progenitors, was maintained in selected cells [36, 37] . Microarray studies confirmed this phenotype, with up-regulation of clusterin, involved in anti-apoptosis [38, 39] , oddskipped related 2 and periostin, as key regulators of pre-osteoblast proliferation [40, 41] and RAB GTPase 1, indicated in cell cycle maintenance [42] . In addition, we observed down-regulation of crystallin ␣B, suggested to have a role in osteogenic differentiation [43] , gremlin 1, a BMP antagonist [44] glycine-rich protein 1, involved in the regulatory processes of development and cellular differentiation [45] and implicated in the non-canonical Wnt signalling pathway [46] . Down-regulated metallothioneins correlate to studies which showed a positive regulatory role of metallothionein isoforms in osteogenesis [47] and reduced serglycin expression with CDM and activin A/FGF-2 suggests a role in the proliferative capacity of these cells [48] . Further genes down-regulated include interleukin 6 (IL-6), necessary for osteoblast signalling in osteoclastogenesis [49] and chemokine C-X-C motif ligands 1 and 6, seen in early neural progenitors during development of the human foetal brain [50] and in mesenchymal cells [51] [52] , similar in locus and morphology to the foetal femur tissue utilized in the current studies [31] . reported [12, 53] and BMP-2 has been shown to positively affect hBMSC proliferation [20, 22, 54] [56] , although the extranuclear expression may be linked to the altered nuclear shape. In contrast to the study of foetal mesenchymal cells by Guillot and coworkers [57] , expression of other hESC markers OCT4 and TRA-1-60 [7, 58, 59] were not seen in the human foetal femur-derived cells. These cultures were further characterized by an increased metabolic activity in comparison to CDM and activin A/FGF-2 conditions, however, suggestive of a differentiating population [33, 60] , as supported by a marked increase in the expression of metabolic gene glutamine-fructose-6-phosphate transaminase 2 [61] and two markers of sterol biosynthesissterol-C4-methyl oxidase-like [62] and squalene epoxidase [63] . Up-regulation of the tRNA splicing endonuclease 15 homolog chromosome 1 open reading frame 19 suggests these populations may also utilise extra mechanisms to maintain cell growth [64] . Down-regulation of differentiation regulatory genes was confirmed with SOX15, involved in skeletal muscle development [65] , and DUSP6, a regulator of the MAP kinase pathway involved osteogenic signal transduction [66] . In addition, increased expression of Wnt inhibitory factor 1, a major antagonist of BMP-signalling [67] , was seen in CDM cultures with BMP-2, as was the synthesizing [80] [81] [82] . The human foetal femur-derived cells are derived initially from predominantly cartilaginous explants [31] and widespread SOX-9 expression in the native femur tissue may be indicative of a mesenchymal condensation, an upstream event of chondrogenesis [37, 83] . 
. Ten genes were identified as representative from the six cluster groups formed at the fourth level of horizontal dendrogram arms and validated with qPCR (Fig. 5). Expression levels for chromosome 1 open reading frame 19 increased in CDM with activin A/FGF-2 cultures over basal and was higher still in CDM plus BMP-2 conditions
. The highest expression for dual specificity phosphatase 6, periplakin and SOX15 were observed in CDM with activin A/FGF-2 conditions, compared to basal and CDM plus BMP-2 cultures (Fig. 5E-G, respectively). In CDM plus BMP-2 conditions, expression of chondroitin synthase-2 was comparable to basal medium (Fig. 5H) but had the highest expression of glutamine-fructose-6-phosphate transaminase 2 (Fig. 5I) and squalene epoxidase (Fig. 5J) in comparison to the other two treatment groups.
Discussion
We have utilized a serum-free CDM for human foetal femur cell expansion and demonstrated the derivation of an undifferentiated population compared to cultures maintained in serum. Furthermore, the addition of BMP-2 provides a novel cellular model for differentiation studies. These studies highlight several key findings; firstly, culture in CDM with activin A and fibroblast growth factor-2 (FGF-2)
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Fig. 1 Culture of human foetal femur-derived cells in a serum-free chemically defined medium (CDM). (A) Cell number in populations maintained for 7 days in either ␣-MEM with 10% foetal calf serum (Basal), ␣-MEM with 10 ng/ml activin A and 12 ng/ml FGF-2 (␣-MEM ϩ A/F) or CDM with activin A/FGF-2 (CDM ϩ A/F) as given by PicoGreen ® double-stranded DNA assay. (B) Specific alkaline phosphatase (ALP) enzymatic activity for three treatment groups, (C) Up-regulation of CLU, OSR2, POSTN and RABGAP1 and (D) Down-regulation of genes CRYAB, CSRP1, EPAS1, GREM1, MT1X and SRGN in CDM plus activin A and FGF-2 cultures compared with basal cultures as validated by quantitative PCR from genome-wide expression array analysis. (E) Total amino acid depletion, appearance and turnover by foetal cells cultured under basal conditions or in CDM in the presence of activin A and FGF-2. Results expressed as mean Ϯ S.D. (A-D) or mean Ϯ S.E.M. (E) with n ϭ 6 (A, B, E) or n ϭ 3 (C,
D
Additionally, although the application of ascorbate/dexamethasone to adult and foetal mesenchymal populations has been previously © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Addition of osteogenic factors to chemically defined medium (CDM)-treated human foetal femur-derived cell cultures. (A) PicoGreen ® doublestranded DNA assay gave cell number for day 10 cultures of CDM with 10 ng/ml activin A and 12 ng/ml FGF-2 (CDM ϩ A/F), CDM with 100 M ascorbate/10 nM dexamethasone (CDM ϩ Asc/Dex), CDM with 150 ng/ml BMP-2 (CDM ϩ BMP-2) or cultures maintained in CDM with activin A and FGF-2 for 5 days and transferred to basal medium for a final 5 days (CDM to Basal). (B) Specific alkaline phosphatase (ALP) activity of culture groups in comparison to basal controls. (C) Typical fibroblastic morphology of basal cultures, also seen in; (D) CDM with activin A and FGF-2, (E) CDM with ascorbate/dexamethasone and; (F) cells pre-treated with CDM plus activin A and FGF-2 before returning to basal conditions. (G) Human foetal cells displayed colonies of cobblestone-like cells, in day 10 CDM cultures with BMP-2 (example denoted by dotted line). (H) CDM plus BMP-2 day 10 cultures labelled with Cell Tracker Green™ CMFDA and DAPI nuclear counterstain. INSET: Cobblestone-like cells and kidney-shaped nuclei (arrows). (I) Cell Tracker Green™ CMFDA and ethidium homodimer-1 (red) labelling for live and necrotic cells, respectively, in CDM plus BMP-2 cultures at day 14 (J) and at day 21. (K) The effect of different culture components on total amino acid depletion, appearance and turnover by foetal femur cells. Bars ϭ 200 m (C-G, I, J), 100 m (H). Results expressed as mean Ϯ S.D. (A, B) or mean Ϯ S.E.M. (K)
,
BMP-2). (A-C) Fluorescence immunocytochemistry staining for type I collagen in respective cultures, as for; (D-F) type II collagen, (G -I) STRO-1, (J-L) SOX-9 and (M-O) SOX-2. Cobblestone-like cells in CDM plus BMP-2 cultures denoted by arrows (C, F, I, L, O).
(HMGCS1); (C) Sterol-C4-methyl oxidase-like (SC4MOL), (D) Wnt inhibitory factor 1 (WIF1), (E) Dual specificity phosphatase 6 (DUSP6), (F) Periplakin (PPL), (G) SRY (sex determining region Y)-box 15 (SOX15), (H) Chondroitin synthase-2 (CHSY-2), (I) Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) and (J) Squalene epoxidase (SQLE
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